CTOs on the Move

Catalyst Pharmaceuticals

www.catalystpharma.com

 
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette`s Disorder.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Tracon Pharmaceuticals

Tracon Pharmaceuticals, is a biopharmaceutical company that licenses, develops, and commercializes targeted therapies for cancer and age-related macular degeneration. The current pipeline takes advantage of established platform technologies to block novel pathways implicated in cancer growth and angiogenesis.

MAPS Public Benefit Corporation

MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics.

SST Corporation

SST Corporation is a Clifton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nucryst Pharmaceuticals

Nucryst Pharmaceuticals Corp. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient`s dendritic cells to activate an immune response specific to the patient`s disease.   Argos` most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. Argos Therapeutics is headquartered in Research Triangle Park, NC. The Company has clinical stage programs in Phase 3 (metastatic renal cell carcinoma), Phase 2b (HIV) and Phase 1a (systemic lupus erythematosus1) development.